If you're looking at the Baillie Gifford US Growth Trust stock (LSE: USA), you're probably drawn to the idea of tapping into the next wave of American technological disruption. It's not just another US index fund. This London-listed investment trust is a high-conviction, actively managed portfolio that aims to find and hold the companies defining the future. But with high growth potential comes significant volatility and unique risks. Let's strip away the marketing gloss and look at what you're really buying, how it's performed, and whether it fits in a modern portfolio.
What You'll Find Inside
What Exactly Is the Baillie Gifford US Growth Trust?
First, let's clear up the basics. The Baillie Gifford US Growth Trust is a closed-ended investment trust listed on the London Stock Exchange (ticker: USA). This structure is crucial. Unlike an open-ended fund (like a unit trust or OEIC), it has a fixed number of shares. This means the managers don't have to sell holdings if investors want out—they just sell their shares to another investor on the stock market. This allows for a truly long-term approach, which is central to Baillie Gifford's philosophy.
The goal is simple in theory, hard in execution: to achieve capital growth by investing primarily in listed US companies with above-average long-term growth potential. The keyword is long-term. We're talking a 5 to 10-year horizon, minimum. The managers, Gary Robinson and Kirsty Gibson, aren't trying to guess next quarter's earnings. They're looking for companies with the potential to multiply in size over decades.
Think Tesla in 2015, not Apple tomorrow.
Key Trust Details at a Glance
Listing: London Stock Exchange, Main Market (USA.L)
Manager: Baillie Gifford & Co.
Portfolio Managers: Gary Robinson, Kirsty Gibson
Ongoing Charges Figure (OCF): ~0.55% (as of latest annual report)
Dividend Policy: Minimal to none; focus is purely on growth.
Structure: Closed-ended Investment Trust.
The Trust's Strategy and Top Holdings
The strategy is unapologetically concentrated and growth-focused. They typically hold between 25 and 50 stocks. That's it. No filler, no attempt to hug the S&P 500 index. This is where many investors get nervous—or excited. The portfolio is built around a few big themes: technological disruption, healthcare innovation, and new consumer and business models.
They look for companies with what they call "positive optionality"—the potential for the business to expand into massive, unforeseen new markets. A classic example is Amazon starting as an online bookstore. The trust wants to own these companies before the world fully understands their potential, and hold them through the inevitable volatility.
Who's in the Portfolio? A Look at the Top 5
The concentration is evident in the top holdings. As of the latest factsheet, a significant portion of the trust's assets is in a handful of names. This isn't diversification in the traditional sense; it's conviction.
| Company | Sector | % of Portfolio (Approx.) | The Trust's Thesis (Simplified) |
|---|---|---|---|
| Tesla | Automotive / Energy | ~9-12% | Bet on the transition to electric vehicles and Tesla's potential in energy storage and AI, not just cars. |
| Amazon | Consumer Discretionary / Tech | ~8-10% | More than retail; dominance in cloud computing (AWS) and advertising. A platform business. |
| Moderna | Healthcare | ~6-8% | mRNA technology as a platform for vaccines and potentially treating other diseases like cancer. |
| NVIDIA | Semiconductors | ~5-7% | The foundational pick-and-shovel play for artificial intelligence and accelerated computing. |
| Zoetis | Healthcare (Animal Health) | ~4-6% | Bet on the long-term trend of pet humanisation and spending on animal healthcare. |
You'll notice these aren't obscure biotech startups. They are large, well-known companies where Baillie Gifford believes the growth story is far from over. The nuance is in the size of the bet. Holding nearly 10% in Tesla is a statement most passive funds would never make.
Performance, Fees, and Key Metrics
Past performance isn't a guide to the future, but it shows how the strategy plays out. The trust has been a rollercoaster. It soared during the 2020-2021 growth stock mania, significantly outperforming the S&P 500. Then it crashed harder during the 2022 bear market when interest rates rose and growth stocks were hammered.
This is the essential trade-off. Over the long term (since its launch in 2018), it has struggled to beat the S&P 500 on a net asset value (NAV) basis, according to data from the Association of Investment Companies. The share price return has been further impacted by the trust's discount (more on that below).
The Ongoing Charges Figure (OCF) is around 0.55%, which is reasonable for an active global growth fund but expensive compared to a US ETF like the Vanguard S&P 500 UCITS ETF (TER: 0.07%). You're paying for active stock selection and that long-term, patient capital structure.
One critical metric for investment trusts is the premium/discount. The trust's shares can trade above (premium) or below (discount) the underlying value of its assets (NAV). Recently, it has often traded at a discount, sometimes widening to over 10%. This can be a headwind for returns or, if you buy at a deep discount, a potential tailwind.
The Risks and Potential Drawbacks
Let's be blunt about the downsides. I've seen investors jump in after reading about the exciting holdings without appreciating these risks.
Extreme Volatility: This is not a core holding for the faint-hearted. When growth stocks fall out of favour, this trust will likely fall more than the market. The 2022 drawdown was over 50%. Can you stomach that without selling?
Manager Risk & Style Out of Favour: You're betting entirely on Baillie Gifford's growth-focused team and their stock picks. If their style is wrong for a market cycle (like a prolonged high-interest-rate environment), the trust will lag.
Currency Risk: The trust's assets are in US dollars, but you buy shares in British pounds. A strong pound against the dollar reduces your returns, and vice-versa.
The Discount/Premium Wildcard: The share price mechanism adds a layer of complexity. You're not just betting on the stocks, but on market sentiment towards the trust itself. Buying at a 15% discount feels great until it moves to a 20% discount.
A common mistake is treating this like a diversified US market fund. It's not. It's a satellite holding, a concentrated bet on a specific investment philosophy.
How to Buy and What Are the Alternatives?
You buy shares in the Baillie Gifford US Growth Trust just like any other UK stock. Use your regular online share dealing platform or ISA/SIPP provider (e.g., Hargreaves Lansdown, Interactive Investor, AJ Bell). Search for ticker USA or the full name.
Before you hit buy, consider the alternatives. What's your actual goal?
- For Broad, Low-Cost US Exposure: A S&P 500 ETF (e.g., VUSA or CSP1) is the obvious, cheaper choice. You'll get the market return with minimal fuss.
- For Active Growth Management with Diversification: Look at open-ended global growth funds, even from Baillie Gifford like the Scottish Mortgage Investment Trust (which is global, not just US) or their open-ended funds. They offer a similar philosophy but with different geographic and stock-specific risks.
- For Direct Thematic Exposure: If you specifically believe in the future of AI, robotics, or genomics, there are ETFs for those themes. You'd be taking on thematic risk instead of manager risk.
The Baillie Gifford US Growth Trust sits in a niche: for investors who want a high-conviction, actively managed, purely US-focused growth portfolio and understand the closed-ended structure. It's a specific tool for a specific job.
